Newstral
Amgen
- FDA Approval of Alvotech/Teva Ustekinumab Biosimilarjdsupra.com
- EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed for Lack of Jurisdictionjdsupra.com
- MDL Panel Grants Transfer of Aflibercept BPCIA Casejdsupra.com
- Genentech and Dr. Reddy’s Settle BPCIA Litigation Against Proposed Rituxan Biosimilar DRL_RIjdsupra.com
- The Pleading Standard for Complex Technology? It's Complex.jdsupra.com
- Will Biopharma Companies Shun Vaccine R&D In A New Pandemic?Forbes
- PA2 Bio’s new CEO aims to grow platformpacbiztimes.com
- DManager of long/short mutual fund touts Amgendcourier.com
- Patent Litigation Update 2024jdsupra.com
- Boeing: Hold board of directors accountableSeattle Times
- The First Prolia® / Xgeva® Biosimilar Approvals in the U.S.jdsupra.com
- FDA Approves Three Interchangeable Biosimilar Drugs in 2024jdsupra.com
- POur view: Housing crisis is spiraling and hurting the workforcepacbiztimes.com
- FDA Approves Sandoz Denosumab Biosimilarsjdsupra.com
- A frenzy of innovation in obesity drugs is under wayThe Economist
- Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilarjdsupra.com
- Ozempic Is a Brain DrugThe Atlantic
- Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigationjdsupra.com
- PVentura County least affordable area in nation to buy a homepacbiztimes.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.